The 16th International Gastric Cancer Congress (IGCC 2025), organized by the International Gastric Cancer Association (IGCA), will take place in Amsterdam, the Netherlands, from May 7 to 10, 2025. The latest results on Henlius’ self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (serplulimab, trade name: Hetronifly^® in Europe) will be presented at the congress. Among them, a phase 2 study evaluating serplulimab combined with concurrent chemoradiotherapy as neoadjuvant treatment for resectable esophagogastric junction adenocarcinoma will be orally presented.

HANSIZHUANG is the world’s first anti-PD-1 mAb for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) and has been approved for marketing in over 30 countries and regions, including China, Europe and Southeast Asia. Up to date, it has been approved for the treatment of squamous non-small cell lung cancer (sqNSCLC), ES-SCLC, esophageal squamous cell carcinoma (ESCC) and non-squamous non-small cell lung cancer (nsNSCLC). Focus on lung and gastrointestinal cancer, the synergy of HANSIZHUANG with in-house products of the company and innovative therapies are being actively promoted. The company has initiated over 10 clinical trials on immuno-oncology combination therapies in a wide variety of indications with more than 4,900 subjects enrolled in China, the U.S., Japan, Turkey, Poland, Georgia and other countries and regions. In the field of gastrointestinal cancers, the company continues to explore therapeutic research in colorectal cancer and gastric cancer. The company is actively advancing a phase 3 clinical trial of HANSIZHUANG plus chemotherapy as neoadjuvant/adjuvant therapy for gastric cancer. The phase 3 stage of the international multi-centre clinical trial (ASTRUM-015) of serplulimab in combination with bevacizumab and chemotherapy in first-line treatment of metastatic colorectal cancer (mCRC) has dosed the first patients in China, Indonesia and Japan, potentially making it the first anti-PD-1 mAb in non-MSI-H mCRC worldwide.

Details of the results of serplulimab to be presented at IGCC 2025 are as follows:

Title: Neoadjuvant Serplulimab with Concurrent Chemoradiotherapy in Resectable Esophagogastric Junction Adenocarcinoma: Phase 2 Updated Results

Number: oral abstract 01.1.13

Oral presentation time: 2025/5/8（UTC+2）

Session: Session 2b：radiation oncology

Presenter: Lin Zhao, Peking Union Medical College Hospital

Title: Efficacy and Safety of Neoadjuvant Anti-PD-1, Thymosin, and SOX in cStage III Gastric Cancer

Session: Poster Session 

Number: P684

PI: Hao Xu, Zekuan Xu, Jiangsu Province Hospital